After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Apellis Pharmaceuticals Inc. (APLS) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.03, or 0.07%, to $43.51. The Apellis Pharmaceuticals Inc. has recorded 12,123 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Apellis Pharmaceuticals to Present at Upcoming Investor Conferences.
APLS belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $43.48 and fluctuated between $44.18 as its day high and $41.20 as its day low. The current market capitalization of Apellis Pharmaceuticals Inc. is $4.97B. A total of 1.81 million shares were traded on the day, compared to an average of 4.66M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, APLS has seen 10 BUY and 14 SELL insider trades, representing the acquisition of 247,087 and the disposition of 136,318 shares. Over the last 12 months, there were 87 BUYs and 124 SELLs from insiders. Insiders purchased 2,529,174 shares during that period but sold 1,695,301.
In the most recent transaction, Francois Cedric sold 150,000 shares of APLS for 41.75 per share on Sep 01. After the transaction, the Chief Executive Officer now owns 424,655 company shares. In a previous transaction on Aug 31, Chopas James George sold 551 shares at 41.23 per share. APLS shares that VP/Chief Accounting Officer owns now total 30,312.
Among the insiders who sold shares, Deschatelets Pascal disposed of 12,000 shares on Aug 08 at a per-share price of $23.66. This resulted in the Chief Scientific Officer holding 1,053,313 shares of APLS after the transaction. In another insider transaction, Machiels Alec sold 1,250 shares at $64.79 per share on Jul 17. Company shares held by the Director now total 267,641.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for APLS in the last 3 months, the mean price target is $65.29 with high estimates of $95.00 and low estimates of $29.00. In terms of 52-week highs and lows, APLS has a high of $94.75 and a low of $19.83.
As of this writing, APLS has an earnings estimate of -$1.16 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of -$0.77 per share and a lower estimate of -$1.47. The company reported an EPS of -$1.56 in the last quarter, which was -6.80% lower than expectations of -$1.46.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. APLS’s latest balance sheet shows that the firm has $700.55M in Cash & Short Term Investments as of fiscal 2021. There were $210.22M in debt and $131.85M in liabilities at the time. Its Book Value Per Share was $2.89, while its Total Shareholder’s Equity was $198.66M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for APLS is Buy with a score of 4.21.